Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Kennedy repeatedly refused to acknowledge scientific consensus that childhood vaccines don’t cause autism and that COVID-19 ...

Merck shares fell in pre-market US trade after the drugmaker posted lower sales of its HPV vaccine Gardasil – with shipments to China paused - and signalled a weaker 2025 outlook.

Merck said it expected sales of $64.1 billion to $65.5 billion in 2025 and adjusted earnings of $8.88 to $9.03 a share. Both forecasts came in below the average analyst expectation for revenue of ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

Follow along today for ongoing coverage of Robert F. Kennedy Jr.'s second Senate confirmation hearing.  | Coverage of Robert ...

The Senate Finance Committee is voting Tuesday on whether to move Robert F. Kennedy Jr.’s nomination forward. All eyes are on ...

OMV faces impacts from U.S. tariffs in certain areas, though its exposure in North America is relatively low, CFO Reinhard ...

Vodafone's CEO said on Tuesday that the European Commission could learn lessons from Britain when it came to assessing ...